Chip maker AMD is investing $20 million in AI drug startup Absci, which will use AMD chips and software for drug development.

Strategists at HSBC led by Frank Lee lowered their price target on the shares to $110 from $200 and cut the rating to Reduce ...

AMD announced its Ryzen AI Max processors at CES, ushering in a new series of AMD -based AI PCs and laptops. The chipmaker ...

HSBC analysts on Wednesday downgraded AMD (NASDAQ:AMD) stock to Reduce from Buy, and nearly halved their price target to $110 from $200, citing a less competitive AI GPU roadmap.

At the top of the lineup is the Ryzen AI Max+ 395, featuring 16 CPU cores, 40 GPU cores, and support for up to 128GB of ...

The $20 million deal gives the chip supplier a toehold in the life-sciences market, a strategy it plans to replicate in other ...

HSBC analyst Frank Lee sees that trend continuing, and lowered his price target on AMD shares by $90, to $110 per share, and ...

AMD announces its new Ryzen AI Max+ 'Strix Halo' APU with 16 cores, 32 threads of Zen 5 CPU, 40 CUs of RDNA 3.5 GPU, up to ...

The next-generation GPUs will be available in the first quarter of 2025. Plus, AMD shows upcoming AI chips for mobile ...

Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct™ accelerators and ROCm™ software to power ...

MSI just announced the new MSI Venture line-up at CES 2025. Here's a look at these new AI PCs, their specs, and everything we ...

AMD has announced that AMD Ryzen AI PRO processors will power new Dell Pro devices. These new PCs will be the first Dell ...